Disease control in patients treated with naxitamab for refractory/relapsed high-risk neuroblastoma

被引：0
|
作者：
Mora, Jaume
Chan, Godfrey C.
Morgenstern, Daniel A.
Amoroso, Loredana
Nysom, Karsten
Faber, Joerg
Wingerter, Arthur
Bear, Melissa
Rubio-San-Simon, Alba
Tornoe, Karen
Koep, Sharif
During, Maria
Kushner, Brian H.
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 17期
关键词：
D O I：
10.1158/1538-7445.PEDIATRIC24-B055
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B055
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Patterns of improvement following initial response in patients treated with naxitamab for relapsed/refractory high-risk neuroblastoma
    Mora, Jaume
    Chan, Godfrey C.
    Morgenstern, Daniel A.
    Amoroso, Loredana
    Nysom, Karsten
    Faber, Joerg
    Wingerter, Arthur
    Bear, Melissa
    Rubio-San-Simon, Alba
    Tornoe, Karen
    Duering, Maria
    Kushner, Brian H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Naxitamab chemo-immunotherapy regimens other than with irinotecan/temozolomide for patients with relapsed/refractory high-risk neuroblastoma
    Larrosa, Crstina
    Simao Rafael, Margarida
    Pablo Munoz, Juan
    Gorostegui, Maite
    Castaneda Heredia, Alicia
    Garraus, Moira
    Mora, Jaume
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Naxitamab-related adverse events within and across treatment cycles in patients with relapsed/refractory (R/R) high-risk neuroblastoma
    Mora, Jaume
    Chan, Godfrey C.
    Morgenstern, Daniel A.
    Amoroso, Loredana
    Nysom, Karsten
    Faber, Joerg
    Wingerter, Arthur
    Bear, Melissa
    Rubio-San-Simon, Alba
    Eldridge, James
    Tornoe, Karen
    Duering, Maria
    Kushner, Brian H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Naxitamab treatment for relapsed or refractory high-risk neuroblastoma: Outcomes from the first prespecified analyses of the Pivotal 201 Trial
    Mora, J.
    Bear, M.
    Chan, G.
    Morgenstern, D. A.
    Nysom, K.
    Tornoe, K.
    Sorensen, P. S.
    Kushner, B.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S956 - S956
  • [5] Oxaliplatin and Doxorubicin for Relapsed or Refractory High-Risk Neuroblastoma
    Tran, Hung C.
    Marachelian, Araz
    Venkatramani, Rajkumar
    Jubran, Rima F.
    Mascarenhas, Leo
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2015, 32 (01) : 26 - 31
  • [6] OXALIPLATIN AND DOXORUBICIN TREATMENT FOR RELAPSED AND REFRACTORY HIGH-RISK NEUROBLASTOMA
    Hung Tran
    Marachelian, Araz
    Venkatramani, Rajkumar
    Jubran, Rima
    Mascarenhas, Leo
    PEDIATRIC BLOOD & CANCER, 2013, 60 : S73 - S73
  • [7] Hypofractionated Palliative Radiotherapy for Relapsed and Refractory High-Risk Neuroblastoma
    Koelker-Wolfe, E. R.
    Marcus, K. J.
    Dubois, S. G.
    Shusterman, S.
    Ioakeim-Ioannidou, M.
    Yock, T. I.
    MacDonald, S.
    Haas-Kogan, D. A.
    Liu, K. X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E487 - E488
  • [8] Hypofractionated Palliative Radiotherapy for Relapsed and Refractory High-Risk Neuroblastoma
    Koelker-Wolfe, Ellery
    Marcus, Karen J.
    Dubois, Steven G.
    Catalano, Paul J.
    Shusterman, Suzanne
    Ioakeim-Ioannidou, Myrsini
    Elhalawani, Hesham
    Yock, Torunn I.
    Macdonald, Shannon M.
    Haas-Kogan, Daphne A.
    Liu, Kevin X.
    CURRENT ONCOLOGY, 2025, 32 (03)
  • [9] Outpatient administration of naxitamab in combination with granulocyte-macrophage colony-stimulating factor in patients with refractory and/or relapsed high-risk neuroblastoma: Management of adverse events
    Mora, Jaume
    Chan, Godfrey C.
    Morgenstern, Daniel A.
    Nysom, Karsten
    Bear, Melissa K.
    Tornoe, Karen
    Kushner, Brian H.
    CANCER REPORTS, 2023, 6 (01)
  • [10] Adverse Reaction Reporting for Naxitamab in Chinese Expanded Access Treatment for Relapsed/Refractory High-Risk Neuroblastoma at the Children's Hospital of Fudan University
    Qian, Xiaowen
    Zhang, Dufei
    Li, Kai
    Chen, Weiming
    Zhuang, Peijun
    Wang, Hongsheng
    Lei, Zhixian
    Li, Yan
    Eldridge, James
    Dong, Kuiran
    Zhai, Xiaowen
    DRUGS-REAL WORLD OUTCOMES, 2025, 12 (01) : 115 - 123
12345